Showing results (151-160 of 165) with videos related to
Sort By:
Pageof 17
The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.The Lancet. Respiratory Medicine|July 26, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyJin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, et al.The New England Journal of Medicine|October 22, 2025
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, <i>EGFR</i>-Mutated Advanced NSCLCWenfeng Fang, Lin Wu, Xiangjiao Meng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 StudyXinghao Ai, Yueyin Pan, Jianhua Shi, et al.Plos Genetics|April 20, 2016
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung CancerLiyan Jiang, Jiaqi Huang, Brandon W Higgs, et al.Cancer Communications (London, England)|October 26, 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical studyJie Zhang, Yueyin Pan, Qin Shi, et al.Theranostics|January 4, 2021
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinomaTao Jiang, Liyan Jiang, Xiaorong Dong, et al.The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2022
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lu, Yiping Zhang, Guojun Zhang, et al.European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.Pageof 17